VISEN Pharmaceuticals

HKSE • Healthcare • Drug Manufacturers - Specialty & Generic • Quote as of 10/30/2026

Company Profile

IndustryDrug Manufacturers - Specialty & Generic

SectorHealthcare

ExchangeHKSE

Market Capitalization1,661.29 mln

Float27.67 mln

Earnings Date04/01/2027

Piotroski F-Score

3 / 9

Below average

1-Year Forecast

50.32

Transformational upside

Relative Strength

4 / 100

Severely lagging

Debt / Equity

0.26

Very low leverage

Pre-Tax Margin

-675%

Severely loss-making

ROE

-31.26

Deeply negative

Business Description

VISEN Pharmaceuticals is a China-based company focused on bringing innovative hormone treatments to patients across the Chinese Mainland. Founded in 2018 and headquartered in Suzhou, the company is advancing a pipeline of long-acting therapies targeting conditions such as growth hormone deficiency, achondroplasia, and hypoparathyroidism. VISEN works alongside partners including Shanghai Pharmaceutical and United Family Healthcare to support the development and distribution of its treatments.

Key Fundamentals

EPS-2.42

ROE-31.26

RPS0.22

ROIC-86.06

ROA-25.89

EBITDA, mln-259

EV / EBITDA-6.42

EV / EBIT-6.32

Revenue, mln39.56

EV / Revenue42.07

Quote Details

Last 13.93

Change -0.07 (-0.5%)

Open 13.50

Volume 28,100

Turnover 391,433

Average Volume 10,343

Financial Ratios

Pre-Tax Profit Margin-675

Leverage Ratio1.32

Current Ratio4.00

Price / Book2.64

Price / Tangible Book2.64

Debt / Equity0.26

Price / Sales51.58

Financial Strength

Altman Z-Score2.64

Piotroski F-Score 3 / 9

1-Year Target Price50.32

Price Performance & Relative Strength

Period	Price Performance	Relative Strength
1 Week	-8.36%	15 / 100
1 Month	-24.78%	12 / 100
2 Months	-27.07%	19 / 100
6 Months	-44.72%	17 / 100
1 Year	-66.19%	9 / 100